Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study
ConclusionsMetformin administration may be associated with reduced mortality in patients with surgically resected breast cancer, particularly in the HT+/HER2 Tx − group. Clinical trials investigating metformin as a combination agent in breast cancer should stratify patients by curative resection, intrinsic subtype, the presence of T2DM, and the use of insulin.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Health Insurance | HER2 | Hormonal Therapy | Hormones | Insulin | Insurance | Metformin | South Korea Health | Study | Women